Docetaxel and S-1 as adjuvant chemotherapy for pathological stage II, IIIA, IIIB gastric cancer

Phase 2

• Conditions: Pathological stage II, IIIa, or IIIb gastric cancer

• Registration Number: JPRN-UMIN000000857
• Lead Sponsor: Dept. of Surgery and Science, Kyushu University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-10-19
• Study Completion: 2009-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. 2. Contraindication to S-1 3. Under treatment with flucytosine, phenytoin, or warfarin 4. Past history of severe drug hypersensitivity. 5. Uncontrolled medical conditions (e.g., Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray, malignant hypertension, congestive heart failure, myocardial infarction in previous 6 months, arrhythmia requiring treatment, hemorrhage, diabetes). 6. Hepatitis B/C 7. Diarrhea 8. Pregnant or lactating women and women of child bearing potential not using contraception 9. Severe peripheral edema. 10. Grade 2 or greater peripheral neuropathy. 11. HIV positive. 12. Patients judged by the investigator as unfit to be enrolled in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified